



**Moorfields  
Eye Hospital**  
NHS Foundation Trust



## Monthly Finance Performance Report

**For the period ended 30<sup>th</sup> April 2023 (Month 01)**

---

**Presented by**

Jonathan Wilson; Chief Financial Officer

---

**Prepared by**

Justin Betts; Deputy Chief Finance Officer  
Amit Patel; Head of Financial Management  
Lubna Dharssi, Head of Financial Control  
Richard Allen; Head of Income and Contracts

---



# Monthly Finance Performance Report

For the period ended 30th April (Month 01)



## Key Messages

### Statement of Comprehensive Income

<b>Financial Plan and Performance</b>	<p>The full year plan is a £2.98m surplus, however the trusts annual plan and NHS clinical income remains subject to further national plan submissions and NHS clinical income contracts being received.</p> <p>For April the Trust is reporting:-</p> <ul style="list-style-type: none"><li>a £2.73m deficit against a planned deficit of £3.00m, a favourable variance of £0.27m</li></ul>
£2.98m Full year surplus plan	
£2.73m deficit in month	
<b>Income</b>	<p>Total trust income was £20.5m in April, a favourable variance of £0.50m. Key points to note are:-</p> <ul style="list-style-type: none"><li>NHS Clinical activity income in April has been estimated based on draft Elective Recovery Funding (ERF) guidance and is subject to finalisation of contracts and confirmation with the ICB.</li><li>Performance against national ERF targets have not been calculated whilst finalised guidance awaited.</li><li>Activity levels achieved have exceeded the Trusts activity plan required to reach the full year 121% ERF target</li></ul>
£20.48m in month (including £1.41m support)	
<b>Expenditure</b>	<p>Pay is reporting expenditure of £13.27m in April, £0.16m adverse to plan.</p> <p>The key points to note are:-</p> <ul style="list-style-type: none"><li>2.1% pay award has been accounted for as per national guidance, pre national settlement agreements.</li><li>Temporary staff costs were £1.85m in April against a trend of £1.79m for the prior 12 months. Temporary staff costs remain higher than the equivalent pre-pandemic period by 18% with agency reporting £0.76m year to date.</li></ul> <p>Non-pay costs were £0.14m adverse against plan in April, predominantly linked to excluded high cost drugs activity being above plan. Pass through income as been reflected within the income overperformance whilst contractual status is awaited.</p>
£21.86m in month (pay, non pay, excl financing)	
<b>Financing and Depreciation</b>	<p>Financing is reporting a favourable variance of £0.07m in month consisting of:-</p> <ul style="list-style-type: none"><li>Interest receivable benefits linked to the trust cash balance and increases in interest rates.</li></ul>
£1.35m in month	

### Statement of Financial Position

<b>Cash and Working Capital Position</b>	<p>The cash balance as at the 30<sup>th</sup> April was £59.8m, a reduction of £0.8m since the end of March 2023.</p> <p>The Better Payment Practice Code (BPPC) performance in April was 91% (volume) and 95% (value) against a target of 95% across both metrics.</p>
<b>Capital</b>	<p>Capital expenditure as at 30th April 2023 totalled £2.5m predominantly due to Oriel expenditure and slippage of 2022/23 commitments in 2023/24.</p>
<b>(both gross capital expenditure and CDEL)</b>	<p>Capital allocations are not yet finalised and subject to ICB allocations and agreement. Initial planning assumptions assume £10.5m for Trust funded capital and £54.8m for externally funded schemes.</p> <p>Internal capital plans are being reviewed and prioritised via the Capital Planning and Oversight Committee given restricted resources in 2023/24.</p>
<b>Use of Resources</b>	<p>Current use of resources monitoring remains suspended.</p>

### Other Key Information

<b>Efficiencies</b>	<p>The trust is reporting £0.03m efficiencies in month, £0.62m adverse to plan.</p>
£4.52m identified	
£0.03m delivered YTD £0.62m adverse	<p>The trust has identified full year savings of £4.52m compared to a plan of £7.81m for 2023/24 with further detail shown on slide seven.</p> <ul style="list-style-type: none"><li>Divisional efficiencies identified total £2.52m</li><li>Central efficiencies including potential productivity gains are reporting £2.0m identified.</li></ul>
<b>Agency Spend</b>	<p>Trust wide agency spend totals £0.8m YTD approximately 6.0% of total employee expenses spend, in excess of national expectations of 3.7%</p> <ul style="list-style-type: none"><li>Temporary staffing controls are being implemented trustwide via Workforce in relation to managing and reporting agency usage and reasons.</li></ul>
£0.8m spend YTD Approximately 6%	

# Trust Financial Performance - Financial Dashboard Summary

## FINANCIAL PERFORMANCE

Financial Performance £m	Annual Plan	In Month			Year to Date				RAG
		Plan	Actual	Variance	Plan	Actual	Variance	%	
Income	£294.9m	(£20.0m)	(£20.5m)	£0.5m	£20.0m	£20.5m	£0.5m	2%	●
Pay	(£156.9m)	£13.1m	£13.3m	(£0.2m)	(£13.1m)	(£13.3m)	(£0.2m)	(1)%	●
Non Pay	(£118.5m)	£8.5m	£8.6m	(£0.1m)	(£8.5m)	(£8.6m)	(£0.1m)	(2)%	●
Financing & Adjustments	(£16.5m)	£1.4m	£1.3m	£0.1m	(£1.4m)	(£1.3m)	£0.1m	5%	●
<b>CONTROL TOTAL</b>	<b>£2.98m</b>	<b>(£3.0m)</b>	<b>(£2.7m)</b>	<b>£0.3m</b>	<b>(£3.0m)</b>	<b>(£2.7m)</b>	<b>£0.3m</b>		●

### Memorandum Items

Research & Development	(£0.20m)	(£0.33m)	(£0.17m)	£0.16m	(£0.33m)	(£0.17m)	£0.16m	48%	●
Commercial Trading Units	-	-	£0.27m	£0.27m	-	£0.27m	£0.27m	0%	●
ORIEL Revenue	(£0.79m)	(£0.07m)	(£0.05m)	£0.02m	(£0.07m)	(£0.05m)	£0.02m	30%	●
Efficiency Schemes	£7.81m	£0.65m	£0.03m	(£0.62m)	£0.65m	£0.03m	(£0.62m)	(95)%	●

## INCOME BREAKDOWN RELATED TO ACTIVITY


Income Breakdown £m	Annual Plan	Year to Date				Forecast		
		Plan	Actual	Variance	RAG	Plan	Actual	Variance
NHS Clinical Income	£184.7m	£12.3m	£11.8m	(£0.5m)	●			
Pass Through	£35.1m	£2.3m	£2.9m	£0.5m	●			
Other NHS Clinical Income	£9.7m	£0.7m	£0.8m	£0.2m	●			
Commercial Trading Units	£40.9m	£2.9m	£3.2m	£0.3m	●			
Research & Development	£15.0m	£0.9m	£1.1m	£0.2m	●			
Other	£9.4m	£0.8m	£0.7m	(£0.1m)	●			
<b>INCOME INCL ERF</b>	<b>£294.9m</b>	<b>£20.0m</b>	<b>£20.5m</b>	<b>£0.5m</b>				

RAG Ratings Red > 3% Adverse Variance, Amber < 3% Adverse Variance, Green Favourable Variance, Grey Not applicable


## PAY AND WORKFORCE

Pay & Workforce £m	Annual Plan	In Month			Year to Date			% Total
		Plan	Actual	Variance	Plan	Actual	Variance	
Employed	(£155.4m)	(£13.0m)	(£11.4m)	£1.6m	(£13.0m)	(£11.4m)	£1.6m	86%
Bank	(£1.0m)	(£0.1m)	(£1.1m)	(£1.0m)	(£0.1m)	(£1.1m)	(£1.0m)	8%
Agency	-	-	(£0.8m)	(£0.8m)	-	(£0.8m)	(£0.8m)	6%
Other	(£0.5m)	(£0.0m)	(£0.1m)	(£0.0m)	(£0.0m)	(£0.1m)	(£0.0m)	0%
<b>TOTAL PAY</b>	<b>(£156.9m)</b>	<b>(£13.1m)</b>	<b>(£13.3m)</b>	<b>(£0.2m)</b>	<b>(£13.1m)</b>	<b>(£13.3m)</b>	<b>(£0.2m)</b>	

### Rolling Pay Spend £m



### Rolling Bank & Agency Spend £m



\*Agency cap levels set by NHSIE

## CASH, CAPITAL AND OTHER KPI'S

Capital Programme £m	Annual Plan	Year to Date				Forecast		
		Plan	Actual	Variance	RAG	Plan	Actual	Variance
Trust Funded	(£10.5m)	(£0.7m)	£0.0m	(£0.7m)	●	(£10.5m)	£0.0m	(£10.6m)
Donated/Externally funded	(£54.8m)	(£3.9m)	(£2.6m)	(£1.4m)	●	(£54.8m)	(£2.6m)	(£52.3m)
<b>TOTAL</b>	<b>£65.4m</b>	<b>£4.6m</b>	<b>£2.5m</b>	<b>(£2.0m)</b>		<b>£65.4m</b>	<b>£2.5m</b>	<b>(£62.8m)</b>


### Key Metrics

	Plan	Actual	RAG
Cash	-	59.8	#DIV/0!
Debtor Days	45	20	●
Creditor Days	45	59	●
PP Debtor Days	65	31	●


### Use of Resources

	Plan	Actual
Capital service cover rating	-	-
Liquidity rating	-	-
I&E margin rating	-	-
I&E margin: distance from fin. plan	-	-
Agency rating	-	-
<b>OVERALL RATING</b>	-	-

### Net Receivables/Ageing £m



# Trust Income and Expenditure Performance



## FINANCIAL PERFORMANCE

Statement of Comprehensive Income £m	Annual Plan	In Month			Year to Date				RAG
		Plan	Actual	Variance	Plan	Actual	Variance	%	
<b>Income</b>									
NHS Commissioned Clinical Income	194.31	12.95	13.23	0.28	12.95	13.23	0.28	2%	●
Other NHS Clinical Income	9.74	0.66	0.81	0.15	0.66	0.81	0.15	23%	●
Commercial Trading Units	40.91	2.92	3.18	0.26	2.92	3.18	0.26	9%	●
Research & Development	14.95	0.94	1.12	0.18	0.94	1.12	0.18	19%	●
Other Income	9.44	0.81	0.72	(0.09)	0.81	0.72	(0.09)	(11)%	●
<b>Total Income</b>	<b>269.35</b>	<b>18.28</b>	<b>19.06</b>	<b>0.78</b>	<b>18.28</b>	<b>19.06</b>	<b>0.78</b>	<b>4%</b>	●
<b>Operating Expenses</b>									
Pay	(156.90)	(13.11)	(13.27)	(0.16)	(13.11)	(13.27)	(0.16)	(1)%	●
Drugs	(38.71)	(2.53)	(3.02)	(0.49)	(2.53)	(3.02)	(0.49)	(20)%	●
Clinical Supplies	(25.83)	(1.62)	(1.71)	(0.09)	(1.62)	(1.71)	(0.09)	(5)%	●
Other Non Pay	(53.96)	(4.31)	(3.87)	0.44	(4.31)	(3.87)	0.44	10%	●
<b>Total Operating Expenditure</b>	<b>(275.39)</b>	<b>(21.57)</b>	<b>(21.86)</b>	<b>(0.30)</b>	<b>(21.57)</b>	<b>(21.86)</b>	<b>(0.30)</b>	<b>(1)%</b>	●
<b>EBITDA</b>	<b>(6.04)</b>	<b>(3.28)</b>	<b>(2.80)</b>	<b>0.48</b>	<b>(3.28)</b>	<b>(2.80)</b>	<b>0.48</b>	<b>15%</b>	●
Financing & Depreciation	(17.00)	(1.46)	(1.39)	0.07	(1.46)	(1.39)	0.07	5%	●
Donated assets/impairment adjustments	0.52	0.04	0.04	(0.00)	0.04	0.04	(0.00)	(7)%	●
<b>Control Total Surplus/(Deficit) Pre ERF/Block and Top Up Payments</b>	<b>(22.52)</b>	<b>(4.70)</b>	<b>(4.15)</b>	<b>0.55</b>	<b>(4.70)</b>	<b>(4.15)</b>	<b>0.55</b>	<b>12%</b>	●
Elective Recovery Funding	25.51	1.70	1.42	(0.28)	1.70	1.42	(0.28)	(16)%	●
Covid and IFRS16 ICB Contribution	-	-	-	-	-	-	-	-	●
Block funding in excess of activity	-	-	(0.01)	(0.01)	-	(0.01)	(0.01)	-	●
<b>Control Total Surplus/(Deficit) Post ERF/COVID Income</b>	<b>2.98</b>	<b>(3.00)</b>	<b>(2.73)</b>	<b>0.27</b>	<b>(3.00)</b>	<b>(2.73)</b>	<b>0.27</b>	<b>-</b>	●

## Commentary

**Operating Income** Clinical activity levels recorded were 101% for Daycase and 109% for Outpatients during April, with activity-based income totalling £13.23m. Other notable variances included:-

£0.78m favourable to plan pre support

- Clinical income was £13.23m, £0.28m favourable to plan;
- Commercial trading income was £3.18m, £0.26m favourable to plan.
- Research and Development income was £1.12m; £0.18m favourable to plan
- Other Income was £0.72m; £0.09m adverse to plan.

**Employee Expenses** Pay in April is reported as £13.27m against a cumulative trend of £13.03m in the prior 12 months.

£0.16m adverse to plan in month


- Substantive costs remain on trend with the prior year after normalising the 2.1% accrued pay award (pre nationally agreed settlements).
- Bank and agency costs totalled £1.85m in April against a rolling 12 month average of £1.79m.
- Key operational areas where agency continues to be at increased levels are theatre staffing and use of agency Anaesthetists, and expenditure in corporate areas.

**Non Pay Expenses** Non-Pay costs in April were £9.95m against a cumulative trend of £9.47m in the prior 12 months.

£0.07m adverse to plan in month (non pay and financing)

- Drugs expenditure was £0.49m adverse to plan reflecting injection activity higher than planned. Contractual status for re-imbursement for HCD is yet to be finalised. Actual expenditure was £3.02m in month against prior month expenditure of £3.58m.
- Clinical supplies expenditure was £0.09m adverse in month reflecting activity levels above plan. Actual expenditure was £1.71m in April against £1.85m in the prior month.
- Other non-pay was £0.44m favourable in month predominantly linked to unutilised/deferred cost pressure/developments subject to review.

# Trust Patient Clinical Activity/Income Performance




## PATIENT ACTIVITY AND CLINICAL INCOME

ERF	Point of Delivery	Activity In Month				Activity YTD				YTD Income £'000			
		Plan	Actual	Variance	%	Plan	Actual	Variance	%	Plan	Actual	Variance	%
ERF Activity	Daycase / Inpatients	2,405	2,434	29	101%	2,405	2,434	29	101%				
	OP Firsts	9,110	9,663	553	106%	9,110	9,663	553	106%				
	OP Procedures	14,450	16,162	1,712	112%	14,450	16,162	1,712	112%				
<b>ERF Activity Total</b>													
Non ERF Activity	OP Follow Ups	16,751	17,746	995	106%	16,751	17,746	995	106%				
	High Cost Drugs	3,970	4,675	705	118%	3,970	4,675	705	118%				
	Non Elective	226	226	0	100%	226	226	0	100%				
	AandE	6,480	6,309	(171)	97%	6,480	6,309	(171)	97%				
	Other NHS clinical income												
<b>Total</b>		<b>53,392</b>	<b>57,215</b>	<b>3,823</b>	<b>107%</b>	<b>53,392</b>	<b>57,215</b>	<b>3,823</b>	<b>107%</b>				

RAG Ratings Red to Green colour gradient determined by where each percentage falls within the range

## ACTIVITY TREND - ERF COMPONENTS



## Commentary

### Activity plans and ERF

The Trust has an external Elective Recovery Fund (ERF) target of 118% for financially weighted average activity units (WAU) and has a stretch target of 121% in order to contribute towards the Trusts efficiencies and productivity plans shown on slide eight.

The activity plan numbers and charts shown to the left are based on the divisionally agreed activity plans to deliver the 121% target including major developments such as the North East Stratford hub.

### NHS Income

NHS Patient Clinical activity income in April has been estimated based on draft Elective Recovery Funding (ERF) guidance and is subject to confirmation with the ICB.

### ERF Achievement

The calculated ERF performance will not be reported in April until final national guidance has been received.

### Activity performance achievement

The Financial ERF target achievement is comprised of:-

- **Inpatient activity** achieved 101% of activity plans in April (93% in March);
- **Outpatient Firsts Activity** achieved 106% of activity plans in April (102% in March);
- **Outpatient Procedures Activity** achieved 112% % of activity plans in April; (128% in March)

### Non ERF Activity


- **High Cost Drugs Injections** achieved 122% of activity plans in April (117% in March);
- **A&E** achieved 97% of activity plans in April (76% in March);

### Activity Plans

The charts to the left demonstrate the in year activity levels compared to the previous year, including the 121% activity plans, and 2019/20 average activity levels for comparison.

The red line represents average 2019/20 activity levels. Where the upper and lower lines represent upper and lower levels of 2019/20 activity pre additive capacity such as Hoxton and Brent Cross.

# Trust Statement of Financial Position – Cash, Capital, Receivables and Other Metrics




## CAPITAL EXPENDITURE

Capital Expenditure £m	Annual Plan	Year to Date			Forecast		
		Plan	Actual	Variance	Plan	Actual	Variance
Estates - Trust Funded	-	-	(0.0)	(0.0)	-	-	-
Medical Equipment - Trust Funded	-	-	-	-	-	-	-
IT - Trust Funded	-	-	-	-	-	-	-
ORIEL - Trust Funded	-	-	-	-	-	-	-
Commercial - Trust funded	-	-	0.0	0.0	-	-	-
Other - Trust funded	10.5	0.7	(0.0)	(0.7)	10.5	-	-
<b>TOTAL - TRUST FUNDED</b>	<b>10.5</b>	<b>0.7</b>	<b>(0.0)</b>	<b>(0.7)</b>	<b>10.5</b>	-	-
Externally funded	54.8	3.9	2.6	(1.4)	54.8	-	-
<b>TOTAL INCLUDING DONATED</b>	<b>65.4</b>	<b>4.6</b>	<b>2.5</b>	<b>(2.0)</b>	<b>65.4</b>	-	-


Capital Funding £m	Annual Plan	Secured	Not Yet Secured	% Secured
ICS Fair Share Allocation	10.5	-	10.5	-
Cash Reserves - Oriel	-	-	-	-
Cash Reserves - B/Fwd	-	-	-	-
Capital Loan Repayments	-	-	-	-
<b>TOTAL - TRUST FUNDED</b>	<b>10.5</b>	-	<b>10.5</b>	<b>0%</b>
Externally funded	54.6	53.9	0.8	99%
Donated/Charity	0.2	0.2	-	100%
<b>TOTAL INCLUDING DONATED</b>	<b>65.4</b>	<b>54.1</b>	<b>17%</b>	<b>83%</b>

## RECEIVABLES


Net Receivables £m	0-60 Days	60-180 Days	180+ Days	2020/21 +	Total
CCG Debt	(0.2)	(0.0)	-	(0.0)	(0.3)
Other NHS Debt	1.9	0.4	0.5	0.5	3.3
Non NHS Debt	4.6	2.3	0.5	0.8	8.3
Commercial Unit Debt	2.7	1.2	0.6	0.3	4.8
<b>TOTAL RECEIVABLES</b>	<b>9.0</b>	<b>3.9</b>	<b>1.6</b>	<b>1.6</b>	<b>16.1</b>



Net Receivables £m



Ageing £m



## OTHER METRICS

Use of Resources	Weighting	Plan YTD	Score
Capital service cover rating	20%	-	-
Liquidity rating	20%	-	-
I&E margin rating	20%	-	-
I&E margin: distance from financial plan	20%	-	-
Agency rating	20%	-	-
<b>OVERALL RATING</b>		<b>-</b>	<b>-</b>

## STATEMENT OF FINANCIAL POSITION

Statement of Financial Position £m	Annual Plan	Year to Date		
		Plan	Actual	Variance
Non-current assets	-	-	219.5	219.5
Current assets (excl Cash)	-	-	26.8	26.8
Cash and cash equivalents	-	-	59.8	59.8
Current liabilities	-	-	(64.8)	(64.8)
Non-current liabilities	-	-	(67.9)	(67.9)
<b>TOTAL ASSETS EMPLOYED</b>	<b>-</b>	<b>-</b>	<b>173.4</b>	<b>173.4</b>

## Commentary

**Cash and Working Capital** The cash balance as at the 30<sup>th</sup> April was £59.8m, a reduction of £0.8m since the end of March 2023.

**Capital Expenditure** Capital expenditure as at 30<sup>th</sup> April 2023 totalled £2.5m predominantly due to Oriel expenditure and slippage of 2022/23 commitments in 2023/24.

Capital allocations are not yet finalised and subject to ICB allocations and agreement. Initial planning assumptions assume £10.5m for Trust funded capital and £54.8m for externally funded schemes.

Internal capital plans are being reviewed and prioritised via the Capital Planning and Oversight Committee given restricted resources in 2023/24.


**Use of Resources** Use of resources monitoring and reporting has been suspended.

**Receivables** Receivables have reduced by £2.7m to £16.1m since the end of the 2022/23 financial year. Debt in excess of 60 days increased by £1.6m in April, offset by a £4.3m reduction in current debt.

**Payables** Payables totalled £16.7m at the end of April, a reduction of £7.7m since the end of March 2023.

The trust's performance against the Better Payment Practice Code (BPPC) was 91% (volume) and 95% (value) against a target of 95%. Prior month achievement was 97% (volume) and 99% (value).

# Trust Statement of Financial Position – Cashflow




## Commentary

Cash Flow															
Cash Flow £m	Apr Actuals	May Forecast	Jun Forecast	Jul Forecast	Aug Forecast	Sep Forecast	Oct Forecast	Nov Forecast	Dec Forecast	Jan Forecast	Feb Forecast	Mar Forecast	Outturn Total	Apr Forecast	Apr Var
<b>Opening Cash at Bank</b>	<b>60.6</b>	<b>59.8</b>	<b>56.0</b>	<b>53.2</b>	<b>50.9</b>	<b>47.4</b>	<b>49.8</b>	<b>52.4</b>	<b>55.8</b>	<b>46.3</b>	<b>50.6</b>	<b>53.1</b>	<b>60.6</b>		
<b>Cash Inflows</b>															
Healthcare Contracts	19.6	18.8	20.5	19.7	18.9	18.8	21.2	21.2	15.1	21.2	20.2	18.6	233.8	15.4	4.2
Other NHS	5.1	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	13.4	0.8	4.3
Moorfields Private/Dubai	3.0	3.0	3.3	3.2	3.0	3.5	3.8	3.9	3.0	3.7	3.6	3.8	41.0	2.9	0.1
Research	1.2	0.9	0.9	0.9	0.9	0.9	1.6	1.6	1.6	1.6	1.6	1.6	15.2	0.9	0.3
VAT	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	6.1	0.5	0.1
PDC	-	-	-	-	-	-	5.0	5.0	5.0	5.0	5.0	5.0	30.0	-	-
Other Inflows	1.0	-	-	-	-	10.0	-	-	-	-	-	-	11.0	-	1.0
<b>Total Cash Inflows</b>	<b>30.5</b>	<b>24.0</b>	<b>26.1</b>	<b>25.1</b>	<b>24.1</b>	<b>34.5</b>	<b>32.9</b>	<b>32.9</b>	<b>25.9</b>	<b>32.8</b>	<b>31.6</b>	<b>30.2</b>	<b>350.6</b>	<b>20.5</b>	<b>10.1</b>
<b>Cash Outflows</b>															
Salaries, Wages, Tax & NI	(10.9)	(11.0)	(12.0)	(11.2)	(11.2)	(11.2)	(11.2)	(11.2)	(11.2)	(11.2)	(11.2)	(11.2)	(134.7)	(11.0)	0.1
Non Pay Expenditure	(15.7)	(11.2)	(10.9)	(10.9)	(10.9)	(11.1)	(11.4)	(11.5)	(9.6)	(11.7)	(11.7)	(4.6)	(131.2)	(9.8)	(5.9)
Capital Expenditure	(2.7)	(1.0)	(1.0)	(1.0)	(1.0)	(3.0)	(1.0)	(1.0)	(1.0)	(1.0)	(1.0)	(5.4)	(20.5)	(1.1)	(1.6)
Oriel	(0.2)	(2.8)	(3.1)	(2.4)	(2.3)	(3.6)	(4.8)	(3.9)	(11.8)	(2.8)	(2.9)	(2.6)	(43.1)	(3.5)	3.3
Moorfields Private/Dubai	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(21.6)	(1.8)	0.0
Financing - Loan repayments	-	-	-	-	(0.4)	(0.5)	-	-	-	-	(0.4)	(0.5)	(1.8)	-	-
Dividend and Interest Payable	-	-	-	-	-	(0.9)	-	-	-	-	-	(0.9)	(1.8)	-	-
<b>Total Cash Outflows</b>	<b>(31.3)</b>	<b>(27.9)</b>	<b>(28.8)</b>	<b>(27.4)</b>	<b>(27.6)</b>	<b>(32.1)</b>	<b>(30.3)</b>	<b>(29.4)</b>	<b>(35.4)</b>	<b>(28.5)</b>	<b>(29.1)</b>	<b>(26.9)</b>	<b>(354.8)</b>	<b>(27.2)</b>	<b>(4.1)</b>
Net Cash inflows /(Outflows)	(0.7)	(3.9)	(2.8)	(2.3)	(3.5)	2.4	2.6	3.4	(9.6)	4.3	2.5	3.3	-	(6.7)	6.0
<b>Closing Cash at Bank 2023/24</b>	<b>59.8</b>	<b>56.0</b>	<b>53.2</b>	<b>50.9</b>	<b>47.4</b>	<b>49.8</b>	<b>52.4</b>	<b>55.8</b>	<b>46.3</b>	<b>50.6</b>	<b>53.1</b>	<b>56.4</b>	<b>56.4</b>		
<b>Closing Cash at Bank 2023/24 Plan</b>	53.9	50.0	47.2	44.9	41.4	49.8	52.4	55.9	46.3	50.6	53.1	56.4	56.4		
<b>Closing Cash at Bank 2022/23</b>	74.7	71.9	73.0	74.8	75.7	75.8	74.7	73.5	76.1	70.3	71.2	60.6	60.6		

**Cash flow** The cash balance at the 30<sup>th</sup> April was £59.8m, which is £5.9m above plan.

The current financial regime has resulted in block contract payments which gives some stability and certainty to the majority of cash receipts. The trust currently has 82 days (prior month: 83 days) of operating cash.


April saw a cash outflow of £0.7m against a forecast of £6.7m due to higher than expected receipts of NHS income and lower than expected payments. The cash flow forecast is currently being refined in line with the revenue and capital plans.



# Trust Efficiency Scheme Performance



EFFICIENCY SCHEMES PERFORMANCE				TRUST WIDE FORECAST						
Efficiency Schemes £m	Annual Plan	In Month			Year to Date			Forecast		
		Plan	Actual	Variance	Plan	Actual	Variance	Plan	Actual	Variance
City Road	£1.59m	£0.13m	£0.02m	(£0.11m)	£0.13m	£0.02m	(£0.11m)	£1.42m		
North	£1.09m	£0.09m	£0.00m	(£0.09m)	£0.09m	£0.00m	(£0.09m)	£0.15m		
South	£0.72m	£0.06m	£0.00m	(£0.06m)	£0.06m	£0.00m	(£0.06m)	£0.25m		
Ophth. & Clinical Serv.	£1.14m	£0.10m	-	(£0.10m)	£0.10m	-	(£0.10m)	£0.48m		
Estates & Facilities	£0.49m	£0.04m	-	(£0.04m)	£0.04m	-	(£0.04m)	-		
Corporate	£0.77m	£0.06m	£0.01m	(£0.06m)	£0.06m	£0.01m	(£0.06m)	£0.22m		
<b>DIVISIONAL EFFICIENCIES</b>	<b>£5.81m</b>	<b>£0.48m</b>	<b>£0.03m</b>	<b>(£0.45m)</b>	<b>£0.48m</b>	<b>£0.03m</b>	<b>(£0.45m)</b>	<b>£2.52m</b>		
<b>Central</b>										
Productivity/Activity	£2.00m	£0.17m	-	(£0.17m)	£0.17m	-	(£0.17m)	£2.00m		
<b>TRUST EFFICIENCIES</b>	<b>£7.81m</b>	<b>£0.65m</b>	<b>£0.03m</b>	<b>(£0.62m)</b>	<b>£0.65m</b>	<b>£0.03m</b>	<b>(£0.62m)</b>	<b>£4.52m</b>		



## Commentary

**Reporting** Trust efficiencies are managed and reported via the Quality Service Improvement & Sustainability Programme (QSI) board.

**Identified Savings** The divisional reporting segment highlights the level of identified schemes by division and the corresponding risk profile for these schemes.

**In Year Delivery** The trust is reporting efficiency savings achieved of




- £0.03m in month, compared to a plan of £0.65m, a £0.62m adverse variance;
- £0.03m year to date, compared to a plan of £0.65m, £0.62m adverse to plan.

**Productivity/Activity** As outlined on slide five, activity performance and ERF calculations are subject to national guidance and have not been calculated for April reporting. This will be expanded for future reporting

**Risk Profiles** The chart to the left demonstrates the changing risk profiles of identified schemes Trustwide and movements through out the year.

**Forecast** The Trust is forecasting achievement of £4.52m against its efficiency plan of £7.81m

## DIVISIONAL REPORTING & OTHER METRICS



\* charts may include rounding differences